Clinical Trials | September 23, 2025
Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Lacosamide is indicated to treat partial-onset seizures
Lacosamide Injection is used to treat partial-onset seizures.
According to IQVIA sales data for the period ending January 2022, Vimpat tablets market achieved annual sales of approx. US $ 1.7 billion
The company plans to launch the product immediately
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
Subscribe To Our Newsletter & Stay Updated
